Jian Xie Insider Information



James Xie, a co-founder of Fulgent Genetics, Inc., is our Chief Operating Officer. Prior to joining Fulgent, Mr. Xie served as the Senior Vice President of Cogent Inc., a publicly traded biometric identification service and product company from 1996 until 2011. As Chief Operating Officer of Fulgent, Mr. Xie is responsible for managing all global operations, product vision and product engineering. He is focused on unifying all departments to maximize efficiency, drive sustainable growth and inspire continuous innovation.

He received his B.A. in Engineering from Chongqing University in 1987, and has both an M.S. in Industrial Engineering and an M.S. in Computer Science from the University of New South Wales in 1992.  

In his free time, he also is a flight instructor for single-engine, multi-engine, and instrument airplanes. He holds a Commercial Pilot’s License (CPL) and Airline Transport Pilot’s License (ATPL).

What is Jian Xie's net worth?

The estimated net worth of Jian Xie is at least $16.57 million as of May 16th, 2022. Mr. Xie owns 329,701 shares of Fulgent Genetics stock worth more than $16,570,772 as of August 16th. This net worth approximation does not reflect any other assets that Mr. Xie may own. Additionally, Mr. Xie receives an annual salary of $704,620.00 as COO at Fulgent Genetics. Learn More about Jian Xie's net worth.

How old is Jian Xie?

Mr. Xie is currently 56 years old. There are 4 older executives and no younger executives at Fulgent Genetics. The oldest executive at Fulgent Genetics is Mr. Ming Hsieh, Chairman & CEO, who is 66 years old. Learn More on Jian Xie's age.

What is Jian Xie's salary?

As the COO of Fulgent Genetics, Inc., Mr. Xie earned a total compensation package of $704,620.00 in 2021. Mr. Xie earned a salary of $495,920.00, a bonus of $200,000.00, and other compensation of $8,700.00.The highest earning executive at Fulgent Genetics is Mr. Ming Hsieh, Chairman & CEO, who commands a salary of $5,660,000.00 per year. Learn More on Jian Xie's salary.

How do I contact Jian Xie?

The corporate mailing address for Mr. Xie and other Fulgent Genetics executives is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. Fulgent Genetics can also be reached via phone at (626) 350-0537 and via email at [email protected] Learn More on Jian Xie's contact information.

Has Jian Xie been buying or selling shares of Fulgent Genetics?

Jian Xie has not been actively trading shares of Fulgent Genetics over the course of the past ninety days. Most recently, Jian Xie sold 1,269 shares of the business's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $53.38, for a transaction totalling $67,739.22. Following the completion of the sale, the chief operating officer now directly owns 329,701 shares of the company's stock, valued at $17,599,439.38. Learn More on Jian Xie's trading history.

Who are Fulgent Genetics' active insiders?

Fulgent Genetics' insider roster includes John Bolger (Director), Hanlin Gao (Insider), Paul Kim (CFO), and Jian Xie (COO). Learn More on Fulgent Genetics' active insiders.

Are insiders buying or selling shares of Fulgent Genetics?

During the last twelve months, insiders at the sold shares 16 times. They sold a total of 12,774 shares worth more than $1,052,791.11. The most recent insider tranaction occured on June, 2nd when CFO Paul Kim sold 415 shares worth more than $22,866.50. Insiders at Fulgent Genetics own 29.5 % of the company. Learn More about insider trades at Fulgent Genetics.

Information on this page was last updated on 6/2/2022.

Jian Xie Insider Trading History at Fulgent Genetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2022Sell1,269$53.38$67,739.22329,701View SEC Filing Icon  
11/29/2021Sell636$95.42$60,687.12View SEC Filing Icon  
8/30/2021Sell622$91.25$56,757.50311,195View SEC Filing Icon  
8/16/2021Sell1,223$95.12$116,331.76View SEC Filing Icon  
5/28/2021Sell647$73.46$47,528.62337,394View SEC Filing Icon  
5/25/2021Sell2,000$72.21$144,420.00338,041View SEC Filing Icon  
5/20/2021Sell1,000$74.48$74,480.00341,041View SEC Filing Icon  
5/18/2021Sell931$70.71$65,831.01341,041View SEC Filing Icon  
3/9/2021Sell62,000$102.65$6,364,300.00345,476View SEC Filing Icon  
12/2/2020Sell1,000$46.00$46,000.00434,085View SEC Filing Icon  
11/30/2020Sell3,396$43.22$146,775.12434,085View SEC Filing Icon  
11/17/2020Sell3,706$45.34$168,030.04447,585View SEC Filing Icon  
8/28/2020Sell441$30.82$13,591.62601,295View SEC Filing Icon  
8/3/2020Sell1,976$27.86$55,051.36603,712View SEC Filing Icon  
See Full Table

Jian Xie Buying and Selling Activity at Fulgent Genetics

This chart shows Jian Xie's buying and selling at Fulgent Genetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fulgent Genetics Company Overview

Fulgent Genetics logo
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Read More

Today's Range

Now: $49.40
Low: $49.22
High: $50.22

50 Day Range

MA: $55.41
Low: $47.98
High: $63.74

2 Week Range

Now: $49.40
Low: $47.34
High: $109.55

Volume

1,892 shs

Average Volume

327,860 shs

Market Capitalization

$1.50 billion

P/E Ratio

3.93

Dividend Yield

N/A

Beta

1.47